title: Clinical Response to Ingenol Mebutate in Patients With Actinic Keratoses.
abstract: Cryotherapy is the most common treatment for actinic keratosis, but its effect is limited to individual lesions. Several topical drugs, however, are available that, in addition to treating individual actinic keratoses, target field cancerization and thereby act on subclinical lesions. Examples are 5-fluorouracil, imiquimod, diclofenac, and ingenol mebutate. We report on 17 patients with actinic keratoses treated with ingenol mebutate and describe our findings on treatment effectiveness, adherence, and tolerance. Complete and partial response rates were 35% and 53%, respectively. Ninety-four percent of patients fully adhered to treatment and 18% developed severe local reactions. Ingenol mebutate is an effective treatment for actinic keratosis. Although it has a similar rate of local reactions to other treatments available for actinic keratosis, its short treatment regimen favors better adherence.
authors.affiliation: Servicio de Dermatología, Centro de Especialidades de Mollabao, Xestión Integrada Pontevedra-Salnés, Pontevedra, España. Electronic address: anacebey@yahoo.es.
authors.forename: A
authors.initials: A
authors.lastname: Batalla
authors.affiliation: Servicio de Dermatología, Centro de Especialidades de Mollabao, Xestión Integrada Pontevedra-Salnés, Pontevedra, España.
authors.forename: Á
authors.initials: Á
authors.lastname: Flórez
authors.affiliation: Servicio de Dermatología, Centro de Especialidades de Mollabao, Xestión Integrada Pontevedra-Salnés, Pontevedra, España.
authors.forename: C
authors.initials: C
authors.lastname: Feal
authors.affiliation: Servicio de Dermatología, Centro de Especialidades de Mollabao, Xestión Integrada Pontevedra-Salnés, Pontevedra, España.
authors.forename: G
authors.initials: G
authors.lastname: Peón
authors.affiliation: Servicio de Dermatología, Centro de Especialidades de Mollabao, Xestión Integrada Pontevedra-Salnés, Pontevedra, España.
authors.forename: M T
authors.initials: MT
authors.lastname: Abalde
authors.affiliation: Servicio de Dermatología, Centro de Especialidades de Mollabao, Xestión Integrada Pontevedra-Salnés, Pontevedra, España.
authors.forename: L
authors.initials: L
authors.lastname: Salgado-Boquete
authors.affiliation: Servicio de Dermatología, Centro de Especialidades de Mollabao, Xestión Integrada Pontevedra-Salnés, Pontevedra, España.
authors.forename: C
authors.initials: C
authors.lastname: de la Torre
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D017679:Cryotherapy; D004224:Diterpenes / Q000009:adverse effects / Q000627:therapeutic use*; D003875:Drug Eruptions / Q000209:etiology; D004341:Drug Evaluation; D005148:Facial Dermatoses / Q000188:drug therapy; D005260:Female; D006801:Humans; D055623:Keratosis, Actinic / Q000188:drug therapy* / Q000628:therapy; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D012074:Remission Induction; D012189:Retrospective Studies; D012536:Scalp Dermatoses / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: C486592:3-ingenyl angelate; D004224:Diterpenes
keywords: Actinic keratosis; Efectividad; Effectiveness; Ingenol mebutate; Ingenol mebutato; Queratosis actínica; Tratamiento; Treatment